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Abstract 
Purpose: To develop a simple, sensitive and selective method for the determination of 
dextromethorphan and its metabolite, dextrophan in human urine using reversed-phase high 
performance liquid chromatography with UV-spectrophotometric detection (RP-HPLC-UV).  
Methods: Pre-column sample clean-up was carried out by liquid-liquid extraction of the analytes with 
chloroform: isopropanol (70:30) solution after alkalization of 1000 µL sample and spiking of internal 
standard, morphine. The samples were chromatographed in a reversed-phase (C-18) ultra sphere silica 
(5µm particle size and 250 x 4.6 mm I.D). The mobile phase consisted of methanol: acetonitrile: 0.5% 
w/v ammonium acetate (10:10:80) adjusted to pH 2.8 with orthophosphoric acid and pumped through 
the column at 1ml/min flow rate. The analytical method was validated for accuracy and precision as well 
as the recovery of the analytes, dextromethorphan and its metabolite, dextrophan over the 
concentration range of 0.20 to 5.0µg/ml. 
Results: The standard curves were linear over the concentration range of 0.2 to 5.0µg/ml for 
dextromethorphan and dextrorphan. The regression coefficients (R2) of the analytes were >0.99. The 
method was reproducible with coefficient of variation for the analytes being < 10 %. Dextromethorphan 
was well resolved from its metabolite, dextrorphan and the internal standard, morphine. The limits of 
detection of dextromethorphan and dextrorphan were 50ng/ml and the recoveries and accuracies were 
greater than 85 and 90 %, respectively.  
Conclusion: The analytical assay method exhibits good precision and selectivity and it was applied to 
the analysis of dextromethorphan and dextrorphan in urine for the assessment of CYP2D6 activity. 
 
Keywords: Dextromethorphan, Dextrophan, Reversed-phase high performance liquid chromatography, 
CYP2D6 activity, Human urine 
 
Tropical Journal  of Pharmaceutical Research is indexed by Science Citation Index (SciSearch), Scopus, 
International Pharmaceutical Abstract, Chemical Abstracts, Embase, Index Copernicus, EBSCO, African 
Index Medicus, JournalSeek, Journal Citation Reports/Science Edition, Directory of Open Access Journals 




Dextromethorphan (DMP) is the methylated 
dextrorotatory analog of levorphanol (a µ-opioid 
receptor agonist) and is chemically referred to as 
3-methoxy-17-methylmorphinan. DMP is used for 
its antitussive properties for cough suppression 
and pain. The DMP metabolic pathway is 
mediated by O-demethylation to its main 
metabolite, dextrophan (DP) via cytochrome P-
450 2D6 (CYP2D6), and N-demethylation to 3-
methoxymorphinan (3-MEM) via CYP3A4/5 [1]. 
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3-MEM is further metabolized to 3-hydroxy-
morphinan (3-OHM) by CYP2D6. DP and 3-OHM 
are then eliminated via the kidneys after 
glucuronidation [2,3]. There are four phenotypic 
subpopulations that define the rate of drug 
metabolism by CYP2D6: individuals with poor 
(PM), intermediate (IM), extensive (EM), and 
ultrarapid metabolizers (UM) [4]. DMP is a well 
established probe drug used to assess CYP2D6 
function because it is relatively safe and readily 
available as an “over-the counter” medication, 
with only mild adverse effects [5,6]. CYP2D6 
activity is predicted using the metabolic ratio 
(MR) from molar concentration of DMP/DP [7,8]. 
 
Various methods have been described in 
literature for the determination of DMP and DP in 
urine, which include high-performance liquid 
chromatography (HPLC) with fluorescence 
detection [9-13], HPLC with ultraviolet detection 
[14], and gas chromatography with flame 
ionization [15], and mass spectrometric detection 
[16]. Specific quantitation was obtained in most 
of these methods but assay sensitivity was 
inadequate for the determination of the 
metabolites. Also, the lower limit of quantification 
of DMP was insufficient for the accurate 
determination of the DMP/DP ratio. There were 
several interferences from endogenous peaks 
under the chromatographic conditions specified 
in some of these methods thereby complicating 
the quantification of DMP or DP. Additionally, the 
sample preparation procedures described in 
these methods generally suffered from low 
analyte recoveries. Again, the assay selectivity in 
the presence of other metabolites was not 
mentioned and the selectivity of the method in 
urine samples originating from different subjects 
was not evaluated [17]. All these may adversely 
affect the determination of DMP, DP and other 
metabolites. Although the effectiveness of HPLC-
MS technique is very accurate, the equipment is 
rather costly. This study therefore aims to 
develop a simple, cost-effective and sensitive 
HPLC–UV method for the simultaneous 
quantitation of DMP and DP in urine samples in 




Chemicals and reagents 
 
The chemicals and reagents used in this study 
were mostly procured from Sigma Aldrich (St. 
Louis, MO, USA) except where indicated. These 
include sodium chloride, sodium acetate, 
ammonium acetate, chloroform, isoprapanol, 
HPLC grade acetonitrile, HPLC grade methanol, 
sodium hydroxide, potassium dihydrogen 
phosphate and β-glucuronidase. Reference 
standards of dextromethorphan HBr, 
dextrorphan-D-tartrate, morphine sulphate, and 
codeine were procured from Sigma Aldrich. 
Other reagents include methylated spirit (Fischer 
Scientific, USA), glacial acetic acid (BDH, UK), 
ammonium acetate (BDH, UK), orthophosphoric 
acid (BDH, UK), and dextromethorphan 
hydrobromide syrup (Zedex®, Nigeria). 
 
Preparation of standard solutions  
 
Stock solutions of 100µg/ml standard DMP and 
DP were prepared by dissolving 10 mg of each 
separately in 100 ml of distilled water. The stock 
solutions were serially diluted with water to give 
working standard concentrations of 0.2, 0.5, 1.0, 
2.0, 4.0, and 5µg/ml for both DMP and DP. A 
stock solution of 1 mg/ml for the internal 
standard, morphine sulphate, was also prepared 
in water.  
 
Chromatographic conditions and equipment 
 
The liquid chromatographic system used was an 
Agilent 1100 series instrument, (Agilent 
Technologies, USA) made up of quaternary 
pumps, a gradient mixer (Agilent, Germany) with 
a system purge and a variable wavelength (200 - 
800nm) uv-vis detector model CE1100 (Agilent, 
Japan) with an 18µL flow cell and detection was 
done at the wavelength of 278nm. Injection was 
by a Rheodyne model 7725 valve (Cotati, 
California, U.S.A.) fitted with a 20 µL loop and an 
on-line vacuum degasser (Agilent, Japan). The 
HPLC was connected to a HP computer system 
and a printer. The column used was a reversed-
phase (C-18) ultra sphere silica with 5µm particle 
size and 250 x 4.6 mm I.D (Beckman, USA). The 
mobile phase consisted of methanol: acetonitrile: 
0.5 %w/v ammonium acetate (10:10:80) pumped 
through the column at a flow rate of 1ml/min. The 
pH of the mobile phase was adjusted to 2.8 with 
orthophosphoric acid and the analytical run was 
performed at ambient temperature. 
 
Preparation of calibration standards and 
quality control samples for DMP and DP 
 
Blank urine (1 ml) sample was each placed in six 
different extraction tubes and varying aliquots of 
the stock solutions (100μg/ml) of DMP and DP 
were spiked to give concentrations of 0.2, 0.5, 
1.0, 2.0, 4.0, and 5µg/ml for calibration standards 
and 0.2, 0.5, 1.0, 2.0, and 4.0 µg/ml for quality 
control (QC) samples. 20μL of the stock solution 
of the internal standard, morphine sulphate 
(1mg/ml), was spiked to each tube. The samples 
were rendered alkaline with 1M NaOH (0.5 ml) 
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and whirlmixed for 1 min. Chloroform: 
isopropanol (70:30, 3 ml) solution was added to 
each of the tubes and whirlmixed for 1min after-
which the tubes were centrifuged at 2500 rpm for 
10 min. The organic layer was transferred into 
another extraction tube. The extraction process 
was repeated and the pooled organic extract was 
evaporated to dryness in a water bath at 40 oC. 
The residue was reconstituted in 100 μL of 0.1N 
HCl and whirlmixed before injecting 20 µL onto 
the HPLC. The peak area ratio was plotted 
against the concentration of each of the 
compounds injected. The regression analysis 
was carried out using Microsoft Excel 2007. 
Values of the lower limit of quantitation (LLOQ) 
were calculated according to FDA guidelines for 
bioanalytical method validation [18] as at least 
five times the response compared to blank 
response and a precision of 20 % and accuracy 
of 80 – 120 %. 
 
Determination of precision of the method for 
DMP and DP  
 
The assay procedure described under the 
preparation of calibration standards and quality 
control was repeated five times for QC samples 
within the same day (intra-day precision) and five 
times over four days (inter-day precision) both 
expressed as %RSD values. 
 
Absolute recovery and accuracy for DMP and 
DP 
 
The recovery was computed by comparing peak 
areas obtained after extraction of QC samples 
from urine with peak area results after injecting 
working standard solutions at the same 
theoretical concentrations. The accuracy of the 
measurements was assessed based on replicate 
analysis of four QC samples for each compound 
in each run. 
 
Determination of DMP and DP in urine 
 
To 1 ml of urine sample in a centrifuge tube, 20 
µL of the internal standard was added and the 
mixture was incubated for 18 h with 0.5ml of 10, 
000 IU β-glucuronidase. After the incubation, 
DMP and its metabolite DP were extracted under 
alkaline conditions as previously described. The 
residue was reconstituted in 100 µL 0.1N HCl 
and whirlmixed before 20 µL was injected onto 
the HPLC. The metabolic ratio (MR) was 
calculated as the molar concentration ratio of 
dextromethorphan and its O-demethylated 
metabolite, dextrorphan in a 0 - 8 hour cumulated 





Results were expressed as mean ± SD and RSD 
(%) for the precision and recovery assays. 
Statistical analyses were carried out using 
GraphPad InStat software, version 2, and 
Microsoft Excel 2007 (Microsoft Corporation, 




Chromatographic analysis of DMP and DP 
 
The retention time for DMP, DP and the internal 
standard MP were 8.7, 5.3 and 4.2 min, 
respectively, as shown in Fig 1. A representative 
chromatogram of the blank urine sample spiked 
with 2 µg/ml of standard, DMP and DP and the 
internal standard (MP) is presented in Fig 2 .The 
retention times of DMP, DP and MP in the 
sample chromatograms corresponded to those 
obtained from the reference compounds by direct 
injection (Fig 1). These demonstrated that 
chromatographic peaks of DMP, DP and MP 
were well resolved with no interferences from 
endogenous substances in the matrix. 
 
The limit of detection taken as the concentration 
giving a peak of at least five times the baseline 
noise was 20 ng/ml for both DMP and DP using 
1ml sample, while the value of the lower limit of 
quantitation (LLOQ) calculated according to the 
FDA guidelines for bioanalytical method 
validation [18] was 50 ng/ml for both compounds. 
 
Calibration curves for DMP and DP  
 
The standard curve was a graph of the peak area 
ratio (y-axis) versus the concentration (x-axis) of 
each of the compounds and was linear over the 
concentration range of 0.2 to 5.0 µg/ml for DMP 
and DP, in urine. The regression equations for 
the calibration curves for DMP and DP were y = 
1.537x - 0.115 and y = 0.681x - 0.265, 
respectively with the regression coefficients (R2) 
being 0.995 and 0.998 for DMP and DP, 
respectively, which allowed for accurate reading 
of the concentrations of all the test samples. 
 
Precision of the analytical Method for DMP 
and DP  
 
The RSD%, which is a measure of the precision 
ranged from 4.29 to 7.80 % for intra-day run and 
1.90 to 5.26 % for inter-day assay for DMP, while 
RSD% for DP ranged from 1.43 to 7.2 % and  
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Fig 1: HPLC chromatogram following direct injection of test samples containing 2 µg/ml of DMP, DP and internal 
standard, MP. The peak eluting at 4.2 min represents MP while the peaks at 5.3 and 8.7 mins represents DP and 
DMP, respectively 
 
1.85 to 5.23 % for intra-day and inter-day 
precision, respectively as shown in Table 1. 
 
Recovery and Accuracy of DMP and DP   
 
The recovery of DMP and DP from spiked urine 
following extraction ranged from 84.8 to 104.8 %, 
while the accuracy of the analytical method 




The analytical assay method developed in this 
study gave a good resolution of 
dextromethorphan and its main metabolite, 
dextrorphan. When ten blank urine samples 
obtained from different individuals were 
hydrolyzed, cleaned up and injected onto the 
HPLC to check for endogenous interferences, no 
endogenous compound was found to interfere 
with the DMP and DP. Also, few structurally 
related compounds such as codeine as well as 
some inhibitors of CYP2D6 like propranolol were 
assessed to check for possible interferences. 
None of these drugs interfered with the 
determination of the analytes. The analytical 
method therefore gave a good resolution of 
DMP, DP as well as the internal standard MP, 
thus facilitating accurate determination of the 
drug and its metabolite.  
 
The LLOQ for DMP and DP in urine was 50 
ng/ml, which made it possible to monitor the 
unchanged drug and its metabolite in the 
samples. The method was found to be 
reproducible, as indicated by values obtained for 
RSD (< 10 %) for DMP and DP. The recoveries 
and accuracies for the analytes ranged from 84.8 
to 104.8 % and 89 to 110 %, respectively, 
indicating that the method was quite accurate 
and sensitive. The stability of QC samples was 
evaluated for samples stored at −20 oC for 4 
months; at room temperature for 24 h; and after 
three freeze-thaw cycles. Stability of treated 
samples was also assessed after 24 h [18]. In all 
of the conditions, samples preserved their 
potency (> 90 %) during the mentioned periods. 
 
This method emphasized off-column 
pretreatment as a necessary panacea for 
effective extraction and quantitation of DMP and 
DP in urine. In this study, the choice of 
chloroform/isopropanol as the extracting solvent 
resulted in some improved recovery of DMP 
compared to previous reports [14,19]. The 
analytical method employed in this study is one 
of the few methods that can detect DMP and its 
metabolite DP. Besides, the sample preparation 
procedures described in some previous methods 
generally suffered from low analyte recoveries 
[15,20] and in most cases, the selectivity of these 
methods in the presence of a number of other 
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Fig 2: HPLC Chromatogram of spiked urine containing 2 µg/ml each of DMP, DP and internal standard, MP. The 
peak eluting at 4.2 min represents MP while the peaks at approximately 5.3 and 8.8 min represent DP and DMP, 
respectively.  
 







Intra-day precision (n = 5) Inter-day precision (n = 5) Analyte recovery (n = 5) 
Mean 
observed conc 







conc ± SD 
(µg/ml) 
RSD (%) Accuracy (%) (%) ± SD RS`D (%) 
Dextromethorphan 
0.2 0.19 ± 0.015 7.80 95 0.19 ± 0.01 5.26 95  85.3 ± 0.54 0.63 
0.5 0.53 ± 0.031 5.81 106 0.55 ± 0.02 4.05 110 87.1 ± 1.02 1.17 
1.0 1.05 ± 0.045 4.29 105 1.02 ± 0.034 3.33 102 90.4 ± 0.76 0.84 
2.0 1.78 ± 0.082 4.6 89 1.84 ± 0.035 1.90 92 84.8 ± 1.28 1.51 
          
Dextrorphan 
0.2 0.18 ± 0.013 7.2 90 0.21 ± 0.011 5.23 105 90.6 ± 1.08 1.19 
0.5 0.49 ± 0.01 2.5 98 0.51 ± 0.023 4.50 102 90.8 ± 1.06 1.17 
1.0 0.98 ± 0.04 4.1 98 1.04 ± 0.042 4.04 104 94.2 ± 0.80 0.85 




The HPLC method described is a simple, 
sensitive and cost-effective assay technique for 
the determination of dextromethorphan and its 
CYP2D6-mediated metabolite, dextrorphan, in 
urine. The main advantage of the method is the 
use of a simple liquid-liquid extraction process for 
sample clean-up prior to chromatographic 
protocol with good analyte recovery. The newly 
developed method allowed the simultaneous 
determination of dextromethorphan and its main 
metabolite, dextrorphan; it is also suitable for 
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